XML 95 R83.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information - Net Loss For Reportable Segment (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Total revenue $ 51,240   $ 26,425   $ 95,446 $ 42,942
Cost of sales 298   136   536 194
Loss from operations (61,697)   (71,285)   (131,488) (135,714)
Impairment of intangible assets            
Interest and investment income, net 3,155   1,153   5,469 2,040
Change in fair value of related-party convertible note         (332,589) (41,413)
Change in fair value of warrant liabilities (44,190)   3,889   (339,603) 3,441
Interest expense related to revenue interest liability (17,192)   (13,405)   (31,063) (26,939)
Change in fair value of derivative liabilities (692)   1,931   416 7,509
Other income (expense), net 242   (278)   (5,675) (319)
Total other expense, net (168,693)   (21,020)   (731,690) (86,491)
Loss before income taxes and noncontrolling interest (230,390)   (92,305)   (863,178) (222,205)
Income tax expense 0   (269)   (9) (35)
Net loss (230,390) $ (632,797) (92,574) $ (129,666) (863,187) (222,240)
Net loss attributable to noncontrolling interests, net of tax (12)   (19)   (27) (39)
Net loss attributable to ImmunityBio common stockholders (230,378)   (92,555)   (863,160) (222,201)
Reportable Segment            
Segment Reporting [Line Items]            
Total revenue 51,240   26,425   95,446 42,942
Cost of sales 298   136   536 194
Gross profit 50,942   26,289   94,910 42,748
External research and development expense (including amounts with related parties) 10,424   8,552   30,506 14,063
Personnel-related costs 26,602   23,632   52,452 46,697
Equipment, depreciation, and facility costs 13,410   13,111   26,998 26,303
Other research and development costs 10,380   9,941   18,849 16,407
Total internal research and development expense 50,392   46,684   98,299 89,407
Total research and development expense (including amounts with related parties) 60,816   55,236   128,805 103,470
Selling, general and administrative (including amounts with related parties) 51,823   42,338   97,593 74,992
Total operating costs and expenses 112,639   97,574   226,398 178,462
Loss from operations (61,697)   (71,285)   (131,488) (135,714)
Impairment of intangible assets            
Interest and investment income, net 3,155   1,153   5,469 2,040
Change in fair value of related-party convertible note (95,964)   1,169   (332,589) (41,413)
Change in fair value of warrant liabilities (44,190)   3,889   (339,603) 3,441
Interest expense related to revenue interest liability (17,192)   (13,405)   (31,063) (26,939)
Interest expense (14,052)   (15,479)   (28,645) (30,810)
Change in fair value of derivative liabilities (692)   1,931   416 7,509
Other income (expense), net 242   (278)   (5,675) (319)
Total other expense, net (168,693)   (21,020)   (731,690) (86,491)
Loss before income taxes and noncontrolling interest (230,390)   (92,305)   (863,178) (222,205)
Income tax expense 0   (269)   (9) (35)
Net loss (230,390)   (92,574)   (863,187) (222,240)
Net loss attributable to noncontrolling interests, net of tax (12)   (19)   (27) (39)
Net loss attributable to ImmunityBio common stockholders $ (230,378)   $ (92,555)   $ (863,160) $ (222,201)